March 1, 2005

The American University of Sharjah (AUS) and the Arab Science and Technology Foundation (ASTF) signed an MOU on February, 28, 2005 to develop and commercialize a biomedical device invented by two AUS faculty members, Drs. Khaled Assaleh and Hasan Al-Nashash, of the AUS School of Engineering. Chancellor Dr Winfred Thompson represented AUSand President Dr. Abdullah Alnajjar represented ASTF.
 
The device--the fetal heart monitor--uses a mother's electrocardiograph signal to non-invasively and inexpensively monitor the fetal heartbeat.  Called the FECG, the device provides general fetal surveillance during labor, monitors fetal heart rate, can detect cardiac arrhythmia and acidosis, among other uses.  It will also help reduce unnecessary operations.  The current technology is highly invasive, posing a serious risk to the mother and the fetus.  It is also very expensive. 

As stated by Dr. Alnajjar of ASTF, "This step is a culmination of ASTF's efforts to support local research activities, build local scientific and inventive capacity and develop long-lasting relationships with the investment community in the region."  

Dr. Alnajjar further stated that "The move reflects the heated scientific activity currently taking place in Sharjah's University City fueled by the enthusiasm and generosity of His Highness Sheikh Dr. Sultan Bin Mohammed Al-Qassimi, Member of the Supreme Council, Ruler of Sharjah, whose tremendous foresight is guiding the unprecedented progress witnessed in Sharjah's scientific milieu."

Dr. Thompson thanked ASTF for their partnership and stated that "This MOU reflects the scientific innovation currently taking place in AUS.  We are proud of our faculty scientists and scholars who are conducting internationally competitive research and also involving their students in this research--giving our students valuable experiences for their future professions."

The scope of cooperation is the commercialization of the FECG developed by the inventors.  ASTF will fund the filing of an international patent for the FECG for costs of up to 100,000 AED.  ASTF is leading the commercialization efforts.  This may include developing a feasibility study, business plan, and other documents needed to solicit investment and/or licensees.  ASTF and AUS will share profits and intellectual property rights. 

The MOU signing was also attended by senior officials from the government and private sectors.

-Ends-

© Press Release 2005